Merck & Co., Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31)
Merck & Co., Inc. (MRK) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) of $0 for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-28.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncome · last filed 2012-02-28
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-03-31 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for fiscal 2011 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for fiscal 2010 was -$10.00M, a 176.92% decline from fiscal 2009.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for fiscal 2009 was $13.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $0.00 derived: sum of 2 quarters · filed 2012-02-28 | $0.00 derived: sum of 3 quarters · filed 2012-02-28 | $0.00 10-K · filed 2012-02-28 | |||
| 2011-09-30 | $0.00 10-Q · filed 2011-11-08 | $0.00 derived: sum of 2 quarters · filed 2011-11-08 | $0.00 10-Q · filed 2011-11-08 | $0.00 derived: sum of 4 quarters · filed 2012-02-28 | |||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-08 | $0.00 10-Q · filed 2011-08-08 | $0.00 derived: sum of 3 quarters · filed 2012-02-28 | $0.00 derived: sum of 4 quarters · filed 2012-02-28 | |||
| 2011-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2012-02-28 | $0.00 derived: sum of 2 quarters · filed 2012-02-28 | $0.00 derived: sum of 3 quarters · filed 2012-02-28 | -$1.00M derived: sum of 4 quarters · filed 2012-02-28 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $0.00 derived: sum of 2 quarters · filed 2012-02-28 | -$1.00M derived: sum of 3 quarters · filed 2012-02-28 | -$10.00M 10-K · filed 2012-02-28 | |||
| 2010-09-30 | $0.00 10-Q · filed 2011-11-08 | -$1.00M derived: sum of 2 quarters · filed 2011-11-08 | -$10.00M 10-Q · filed 2011-11-08 | -$9.70M 10-Q · filed 2010-11-08 | -$7.50M derived: sum of 4 quarters · filed 2011-11-08 | ||
| 2010-06-30 | -$1.00M 10-Q · filed 2011-08-08 | -$400.00K 10-Q · filed 2010-08-06 | -$10.00M 10-Q · filed 2011-08-08 | -$9.90M 10-Q · filed 2010-08-06 | -$7.50M derived: sum of 3 quarters · filed 2011-08-08 | -$1.90M derived: sum of 4 quarters · filed 2011-08-08 | |
| 2010-03-31 | -$11.00M 10-Q · filed 2011-05-09 | -$6.50M derived: sum of 2 quarters · filed 2011-05-09 | -$900.00K derived: sum of 3 quarters · filed 2011-05-09 | -$1.60M derived: sum of 4 quarters · filed 2011-05-09 | |||
| 2009-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $10.10M derived: sum of 2 quarters · filed 2011-02-28 | $9.40M derived: sum of 3 quarters · filed 2011-02-28 | $13.00M 10-K · filed 2011-02-28 | |||
| 2009-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $4.90M derived: sum of 2 quarters · filed 2010-11-08 | $8.50M 10-Q · filed 2010-11-08 | ||||
| 2009-06-30 | -$700.00K 10-Q · filed 2010-08-06 | $2.90M 10-Q · filed 2010-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |